Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 2/20 | 0.40 |
| ▸ | F2 | P00734 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | PPID | Q08752 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5884516 | 0.88 | MTNR1A (0.41) | SMN1; SMN2ALDH1A1TSHRMIFMTNR1A | |
| SCHEMBL15547346 | 0.83 | MTNR1A (0.43) | SMN1; SMN2ALDH1A1MIFMTNR1AMTNR1B | |
| SCHEMBL1430902 | 0.83 | MIF (0.56) | SMN1; SMN2MIFMTNR1AMTNR1B | |
| SCHEMBL1011206 | 0.78 | MTNR1A (0.60) | ALDH1A1MIFMTNR1AMTNR1BLMNA | |
| SCHEMBL31555289 | 0.77 | F2 (0.56) | MMP8F10F2ALDH1A1TSHR | |
| SCHEMBL6275425 | 0.77 | F10 (0.33) | L3MBTL1SMN1; SMN2MMP8F10F2 | |
| SCHEMBL7699371 | 0.76 | L3MBTL1 (0.45) | L3MBTL1SMN1; SMN2MMP8ALDH1A1TP53 | |
| SCHEMBL3748652 | 0.76 | TRPA1 (0.40) | SMN1; SMN2MIFMTNR1AMTNR1B | |
| SCHEMBL3572821 | 0.74 | SMN1; SMN2 (0.43) | L3MBTL1SMN1; SMN2MMP8ALDH1A1TP53 | |
| SCHEMBL4391737 | 0.74 | ESR1 (0.43) | ALDH1A1MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825256-B2 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| EP-1817030-A2 | INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS | Kalypsys, Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006060424-A2 | INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS | KALYPSYS, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | NOS3, NOS2, NOS1 | L3MBTL1 4819/4885SMN1; SMN2 4446/4885MMP8 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.